Notice of Results

RNS Number : 0934C

Stem Cell Sciences plc

27 August 2008

 

Stem Cell Sciences Plc

Notice of 2008 Half Year Results

Cambridge, UK, 27th August, 2008 - Stem Cell Sciences (AIM: STEM. ASX, STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that the Company's interim results for the six months ended 30th June, 2008 will be released on the 28th August, 2008.

There will be a conference call to discuss these results on 28th August, 2008 at 11.00am BST.

Dial-In Numbers

UK - Toll Free

0808 109 0700

International

[phone]

Conference Call Title: Stem Cell Sciences

7-Day Replay

UK / International: [phone]

Passcode: 2436807

A sound file of the call will also be available at www.stemcellsciences.com 

-ends-

About Stem Cell Sciences Plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash (near Melbourne), Australia and a business development office in San Francisco, USA.

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)
Alastair Riddell, CEO

Giorgio Reggiani, Finance Director
[phone]

Citigate Dewe Rogerson (United Kingdom)
Emma Palmer / Mark Swallow
[phone]

Talk Biotech (Australia)
Fay Weston

[phone]

 

END

 

 

NORVDLBLVVBZBBE